Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nuvectis Pharma, Inc.

Get SEC filing alerts via email and in your feed for Nuvectis Pharma, Inc.

NVCT

Nuvectis Pharma, Inc.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Its key products include NXP800, a small molecule targeting ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, a kinase inhibitor for solid tumors. The company aims to address unmet medical needs in oncology through innovative precision medicines, licensing, and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Nuvectis Pharma, Inc.

1
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports $6.1 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports 42% Increase in R&D Expenses for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports Increased Net Loss and Rising R&D Expenses in Latest Financial Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports $6.3 Million Net Loss for Quarter Ended June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports $5.3 Million Net Loss in Q1 2025, Cash Reserves Increase to $29.9 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports $19 Million Net Loss for Fiscal Year 2024, Focuses on Clinical Development

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Nuvectis Pharma, Inc. Nuvectis Pharma Reports Improved Operating and Net Losses, Raises $8.1M Through ATM Offering

Via official filing (AI summary) | over 1 year ago | 0 comments